Thus, in perfect agreement with the recent ADA-EASD consensus report [6], we also encourage the adoption of GLP-1RA plus SGLT2i combination therapy in T2DM patients with established ASCVD (coronary artery disease, cerebrovascular disease, or peripheral arterial disease) or multiple risk factors for ASCVD (i.e., age 55 years, obesity, dyslipidemia, hypertension, current tobacco use, left ventricular hypertrophy, and/or proteinuria) whose HbA1c remains suboptimal despite initial treatment with only one of these agents
49 There are now several trials in the literature documenting a positive role of orally administered glutathione for the treatment of hyperpigmentation, despite its poor absorption
Due to their vastly different receptor binding profiles and systemic effects, they are not interchangeable
revealed that myocardial ferroptosis occurs during MI [87]